Cilostazol Attenuates Retinal Oxidative Stress and Inflammation in a Streptozotocin-Induced Diabetic Animal Model

References

• Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405–12.
   PubMed Web of Science ®Google Scholar
• Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103. doi:10.1155/2007/95103.
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450–52. doi:10.1096/fj.03-1476fje.
   PubMed Web of Science ®Google Scholar
• Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343–58. doi:10.1016/j.preteyeres.2011.05.002.
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Ogata N, Minamino K, Matsumura M. Leukostasis and pigment epithelium-derived factor in rat models of diabetic retinopathy. Mol Vis. 2007;13:1058–65.
   PubMed Web of Science ®Google Scholar
• Miller JW, Adamis AP, Shima DT, D’Amore PA, Moulton RS, O’Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574–84.
   PubMed Web of Science ®Google Scholar
• Engerman RL, Kern TS, Larson ME. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia. 1994;37:141–44.
   PubMed Web of Science ®Google Scholar
• Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol. 2003;75:95–108.
   PubMed Web of Science ®Google Scholar
• Koya D, Gl K. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859–66.
   PubMed Web of Science ®Google Scholar
• Kowluru RA. Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid Redox Signal. 2005;7:1581–87. doi:10.1089/ars.2005.7.1581.
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20. doi:10.1038/414813a.
   PubMed Web of Science ®Google Scholar
• Son SM. Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes. Diabetes Metab J. 2012;36:190–98. doi:10.4093/dmj.2012.36.3.190.
   PubMedGoogle Scholar
• Du X, Stocklauser-Farber K, Rosen P. Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Radic Biol Med. 1999;27:752–63.
   PubMed Web of Science ®Google Scholar
• Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes. 2002;51:2241–48.
   PubMed Web of Science ®Google Scholar
• Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007;56:337–45. doi:10.2337/db06-0789.
   PubMed Web of Science ®Google Scholar
• Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. Curr Diabetes Rev. 2007;3:3–14.
   PubMedGoogle Scholar
• Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109:366–98. doi:10.1016/j.pharmthera.2005.07.003.
   PubMed Web of Science ®Google Scholar
• Kohda N, Tani T, Nakayama S, Adachi T, Marukawa K, Ito R, Ishida K, Matsumoto Y, Kimura Y. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res. 1999;96:261–68.
   PubMed Web of Science ®Google Scholar
• Omi H, Okayama N, Shimizu M, Fukutomi T, Nakamura A, Imaeda K, Okouchi M, Itoh M. Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res. 2004;68:119–25. doi:10.1016/j.mvr.2004.05.002.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. Jama. 2006;295:547–53. doi:10.1001/jama.295.5.547.
   PubMed Web of Science ®Google Scholar
• Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther. 2005;313:502–09. doi:10.1124/jpet.104.079780.
   PubMed Web of Science ®Google Scholar
• Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kurabayashi M, Kasayama S. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence. Atherosclerosis. 2001;158:121–28.
   PubMed Web of Science ®Google Scholar
• Hattori Y, Suzuki K, Tomizawa A, Hirama N, Okayasu T, Hattori S, Satoh H, Akimoto K, Kasai K. Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc Res. 2009;81:133–39. doi:10.1093/cvr/cvn226.
   PubMed Web of Science ®Google Scholar
• Aizawa T, Wei H, Miano JM, Abe J, Berk BC, Yan C. Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res. 2003;93:406–13. doi:10.1161/01.RES.0000091074.33584.F0.
   PubMed Web of Science ®Google Scholar
• Aoki C, Hattori Y, Tomizawa A, Jojima T, Kasai K. Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo. J Atheroscler Thromb. 2010;17:503–09.
   PubMed Web of Science ®Google Scholar
• Yeh PT, Yang CM, Huang JS, Chien CT, Yang CH, Chiang YH, Shih YF. Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. Ophthalmology. 2008;115:734–737 e731. doi:10.1016/j.ophtha.2007.05.041.
   PubMed Web of Science ®Google Scholar
• Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int. 1999;49:91–102.
   PubMed Web of Science ®Google Scholar
• Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi N, Niki E, et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA. 1998;95:4882–87.
   PubMed Web of Science ®Google Scholar
• Koh JS, Yi CO, Heo RW, Ahn JW, Park JR, Lee JE, Kim JH, Hwang JY, Roh GS. Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. Free Radic Biol Med. 2015;89:54–61. doi:10.1016/j.freeradbiomed.2015.07.016.
   PubMed Web of Science ®Google Scholar
• Kulaksizoglu S, Karalezli A. Aqueous humour and serum levels of nitric oxide, malondialdehyde and total antioxidant status in patients with type 2 diabetes with proliferative diabetic retinopathy and nondiabetic senile cataracts. Can J Diabetes. 2016;40:115–19. doi:10.1016/j.jcjd.2015.07.002.
   PubMed Web of Science ®Google Scholar
• Begonja AJ, Teichmann L, Geiger J, Gambaryan S, Walter U. Platelet regulation by NO/cGMP signaling and NAD(P)H oxidase-generated ROS. Blood Cells Mol Dis. 2006;36:166–70. doi:10.1016/j.bcmd.2005.12.028.
   PubMed Web of Science ®Google Scholar
• Hotta H, Ito H, Kagitani F, Sato A. Cilostazol, a selective cAMP phosphodiesterase inhibitor, dilates retinal arterioles and increases retinal and choroidal blood flow in rats. Eur J Pharmacol. 1998;344:49–52.
   PubMed Web of Science ®Google Scholar
• Hwang DJ, Shin JY, Yu HG. Oral administration of cilostazol increases ocular blood flow in patients with diabetic retinopathy. Korean J Ophthalmol. 2017;31:123–31. doi:10.3341/kjo.2017.31.2.123.
   PubMedGoogle Scholar
• Iwama D, Miyamoto K, Miyahara S, Tamura H, Tsujikawa A, Yamashiro K, Kiryu J, Yoshimura N. Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions. J Thromb Haemost. 2007;5:818–25. doi:10.1111/j.1538-7836.2007.02425.x.
   PubMed Web of Science ®Google Scholar
• Jung KI, Kim JH, Park HY, Park CK. Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. J Pharmacol Exp Ther. 2013;345:457–63. doi:10.1124/jpet.113.203067.
   PubMed Web of Science ®Google Scholar
• Asal NJ, Wojciak KA. Effect of cilostazol in treating diabetes-associated microvascular complications. Endocrine. 2017;56:240–44. doi:10.1007/s12020-017-1279-4.
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Kowluru A, Mishra M, Kumar B. Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res. 2015;48:40–61. doi:10.1016/j.preteyeres.2015.05.001.
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res. 2007;2007:43603. doi:10.1155/2007/43603.
   PubMedGoogle Scholar
• Suzuki K, Uchida K, Nakanishi N, Hattori Y. Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes. Am J Hypertens. 2008;21:451–57. doi:10.1038/ajh.2008.6.
   PubMed Web of Science ®Google Scholar
• Nomura S, Shouzu A, Omoto S, Hayakawa T, Kagawa H, Nishikawa M, Inada M, Fujimura Y, Ikeda Y, Fukuhara S. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost. 1998;80:388–92.
   PubMed Web of Science ®Google Scholar
• Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004;16(Suppl 1):S11–14. doi:10.1038/sj.ijir.3901208.
   PubMed Web of Science ®Google Scholar